- Home
- ATHA vs SABS Comparison
ATHA vs SABS Comparison
Compare ATHA & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- SABS
- Stock Information
- Founded
- ATHA 2011
- SABS 2014
- Country
- ATHA United States
- SABS United States
- Employees
- ATHA N/A
- SABS N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- ATHA Health Care
- SABS Health Care
- Exchange
- ATHA Nasdaq
- SABS Nasdaq
- Market Cap
- ATHA 21.0M
- SABS 19.0M
- IPO Year
- ATHA 2020
- SABS N/A
- Fundamental
- Price
- ATHA $0.27
- SABS $1.19
- Analyst Decision
- ATHA Buy
- SABS Strong Buy
- Analyst Count
- ATHA 4
- SABS 5
- Target Price
- ATHA $11.25
- SABS $11.40
- AVG Volume (30 Days)
- ATHA 209.7K
- SABS 38.1K
- Earning Date
- ATHA 05-14-2025
- SABS 05-19-2025
- Dividend Yield
- ATHA N/A
- SABS N/A
- EPS Growth
- ATHA N/A
- SABS N/A
- EPS
- ATHA N/A
- SABS N/A
- Revenue
- ATHA N/A
- SABS $1,322,410.00
- Revenue This Year
- ATHA N/A
- SABS N/A
- Revenue Next Year
- ATHA N/A
- SABS $25.00
- P/E Ratio
- ATHA N/A
- SABS N/A
- Revenue Growth
- ATHA N/A
- SABS N/A
- 52 Week Low
- ATHA $0.25
- SABS $1.11
- 52 Week High
- ATHA $3.67
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- ATHA 29.05
- SABS 31.84
- Support Level
- ATHA $0.25
- SABS $1.11
- Resistance Level
- ATHA $0.31
- SABS $1.80
- Average True Range (ATR)
- ATHA 0.03
- SABS 0.16
- MACD
- ATHA -0.00
- SABS -0.01
- Stochastic Oscillator
- ATHA 12.38
- SABS 19.74
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.